KROS News and Press, Keros Therapeutics Inc. From 05/04/23

2023-05-04 17:55:53 ET Keros Therapeutics press release ( NASDAQ: KROS ): Q1 GAAP EPS of -$1.26. Cash and cash equivalents as of March 31, 2023 was $351.4 million compared to $279.0 million as of December 31, 2022. For further details see: Keros Therapeutics...

LEXINGTON, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from...

2023-04-30 08:07:34 ET Summary KROS is a small company with three clinical programs. Surprisingly, each program has clinical data. The company is well funded, with good data, and I find it interesting. Keros Therapeutics ( KROS ) is a small-to-medium size company...

2023-04-21 13:55:00 ET Shares of Keros Therapeutics (NASDAQ: KROS) were up 19.5% for the week in early trading Friday, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech company's stock closed last week at $38.79 and rose to as high...

LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering fr...

Keros Therapeutics press release ( NASDAQ: KROS ): Q4 GAAP EPS of -$1.09. Keros reported a net loss of $29.7 million for the fourth quarter and $104.7 million for the year ended December 31, 2022, as compared to a net loss of $6.9 million for the fourth quarter and $58.7 million f...

LEXINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering fr...

LEXINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and...

Cowen has initiated Keros Therpeutics ( NASDAQ: KROS ) with a buy rating saying that two of the company's lead pipeline assets could best treatments in their disease areas. The firm did not set a price target. Analyst Tyler Van Buren said that KER-012 and KER-050, under developmen...

Summary Data is promising for KROS' KER-050 compound; investors are rewarding the company on its novel hypotheses. We performed a deep dive on its most recent readouts on KER-050. Market generated data is supportive and we see potential future upside targets forming. Net-net, ra...